Single application of high-intensity focused ultrasound as primary therapy of localized prostate cancer: Treatment-related predictors of biochemical outcomes

被引:6
|
作者
Pfeiffer, Dietrich [1 ]
Berger, Juergen [2 ]
Gross, Andreas [1 ]
机构
[1] Asklepios Hosp Hamburg Barmbek, Dept Urol, Hamburg, Germany
[2] Univ Med Ctr Hamburg Eppendorf, Ctr Med Expt, Inst Med Biometry & Epidemiol, Hamburg, Germany
关键词
Prostate cancer; High-intensity focused ultrasound; Efficacy; Biochemical failure; Prostate edema; Patient movement;
D O I
10.1016/j.ajur.2014.08.009
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objective: Recent reports on high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer suggest that preoperative risk groups of tumor recurrence are strong predictors of oncological outcomes. The purpose of this study is to determine the prognostic significance of treatment-related factors in relation to patient characteristics for biochemical outcomes after HIFU. Methods: This retrospective single-center study included patients treated from December 2002 to December 2010 for localized prostate cancer with two generations of Ablatherm (R) HIFU devices (A1 and A2). All the patients underwent single HIFU treatment session under the concept of whole-gland therapy. Prostate surgery was performed before HIFU to downsize enlarged glands. Androgen deprivation therapy (ADT) was discontinued before HIFU. Biochemical failure (BCF) was defined as prostate specific antigen (PSA) nadir + 1.2 ng/mL (Stuttgart definition). Predictors of BCF were determined using Cox regression models. As covariates, patient-related factors (age, tumor characteristics, ADT) were compared with treatment-related factors (prostate volume, HIFU device generation, conduct of therapy, prostate edema, patient movement, anesthetic modalities). Results: Three hundred and twenty-three (98.8%) out of 327 consecutive patients were evaluable for BCF. Median (interquartile range) follow-up was 51.2 (36.6-80.4) months. The overall BCF-rate was 23.8%. In multivariate analyses, higher initial PSA-values (Hazard ratio [HR]: 1.03; p < 0.001) and higher D'Amico risk stages (HR: 3.45; p < 0.001) were patient-related predictors of BCF. Regarding treatment-related factors, the A2 HIFU device was associated with a decreased risk of BCF (HR: 0.51; p Z 0.007), while prostate edema had an adverse effect HR: 1.8; p Z 0.027). Short follow-up and retrospective study design are the primary limitations. Conclusion: Success in a single HIFU session depends not merely on tumor characteristics, but also on treatment-related factors. Ablation is more efficacious with the technically advanced A2 HIFU device. Heat-induced prostate edema might adversely affect the outcome. (C) 2015 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier ( Singapore) Pte Ltd. This is an open access article under the CC BY-NC-ND license
引用
收藏
页码:46 / 52
页数:7
相关论文
共 50 条
  • [41] High-intensity focused ultrasound for treating prostate cancer
    Acher, Peter L.
    Hodgson, Dominic J.
    Murphy, Declan G.
    Cahill, Declan J.
    BJU INTERNATIONAL, 2007, 99 (01) : 28 - 32
  • [42] High-intensity focused ultrasound in the management of prostate cancer
    Chaussy, Christian
    Thueroff, Stefan
    EXPERT REVIEW OF MEDICAL DEVICES, 2010, 7 (02) : 209 - 217
  • [43] Hemiablation of Localized Prostate Cancer by High-Intensity Focused Ultrasound: A Series of 35 Cases
    Glybochko, Peter V.
    Amosov, AlexanderV.
    Krupinov, German E.
    Petrovskii, Nikolay V.
    Lumpov, Ilya S.
    ONCOLOGY, 2019, 97 (01) : 44 - 48
  • [44] The role of high-intensity focused ultrasound in prostate cancer
    Lynch J.H.
    Loeb S.
    Current Oncology Reports, 2007, 9 (3) : 222 - 225
  • [45] Transrectal high-intensity focused ultrasound for the treatment of prostate cancer: Past, present, and future
    Mearini, Luigi
    Porena, Massimo
    INDIAN JOURNAL OF UROLOGY, 2010, 26 (01) : 4 - 11
  • [46] High-intensity focused ultrasound therapy for the treatment of prostate cancer: Medium-term experience
    Duran-Rivera, A.
    Montoliu Garcia, A.
    Juan Escudero, J.
    Garrido Abad, P.
    Fernandez Arjona, M.
    Lopez Alcina, E.
    ACTAS UROLOGICAS ESPANOLAS, 2018, 42 (07): : 450 - 456
  • [47] An evaluation of hemi-ablation therapy using high-intensity focused ultrasound in the treatment of localized adenocarcinoma of the prostate
    Ahmed, Hashim Uddin
    Freeman, Alex
    Allen, Clare
    Kirkham, Alex
    Illing, Rowland
    Emberton, Mark
    6TH INTERNATIONAL SYMPOSIUM ON THERAPEUTIC ULTRASOUND, 2007, 911 : 420 - +
  • [48] High-intensity focused ultrasound in prostate cancer: Today's outcomes and tomorrow's perspectives
    Palermo, Giuseppe
    Pinto, Francesco
    Totaro, Angelo
    Miglioranza, Eugenio
    Calarco, Alessandro
    Sacco, Emilio
    Daddessi, Alessandro
    Vittori, Matteo
    Racioppi, Marco
    Dagostino, Daniele
    Gulino, Gaetano
    Giustacchini, Mario
    Bassi, Pierfrancesco
    SCANDINAVIAN JOURNAL OF UROLOGY, 2013, 47 (03) : 179 - 187
  • [49] Morphological analysis of the effects of intraoperative transrectal compression of the prostate during high-intensity focused ultrasound for localized prostate cancer
    Shoji, Sunao
    Hashimoto, Akio
    Nakamoto, Masahiko
    Fukuda, Norio
    Fujikawa, Hiroshi
    Endo, Kazuyuki
    Tomonaga, Tetsuro
    Nakano, Mayura
    Terachi, Toshiro
    Uchida, Toyoaki
    INTERNATIONAL JOURNAL OF UROLOGY, 2015, 22 (06) : 563 - 571
  • [50] High-intensity focused ultrasound (HIFU) in the treatment of localized prostate cancer. From total to focal ablation
    Aboyan, I. A.
    Pakus, S. M.
    Badyan, K., I
    Hasigov, A., V
    Galstyan, A. M.
    ONKOUROLOGIYA, 2020, 16 (03): : 153 - 164